Bausch Health Companies Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Bausch Health Companies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares.
View analyst ratings for Bausch Health Companies or view top-rated stocks.

Wall Street analysts have given Bausch Health Companies a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bausch Health Companies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Bausch Health Companies is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Bausch Health Companies.

Bausch Health Companies Inc. (NYSE:BHC) posted its quarterly earnings data on Monday, May, 3rd. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.10. The company earned $2.03 billion during the quarter, compared to analysts' expectations of $2.08 billion. Bausch Health Companies had a positive trailing twelve-month return on equity of 352.44% and a negative net margin of 12.66%. The company's revenue was up .7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.88 EPS.
View Bausch Health Companies' earnings history.

Bausch Health Companies' stock was trading at $18.45 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BHC shares have increased by 58.9% and is now trading at $29.31.
View which stocks have been most impacted by COVID-19.

Bausch Health Companies issued an update on its FY 2021 earnings guidance on Tuesday, May, 18th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $8.60 billion-$8.80 billion.

9 brokers have issued 12 month price targets for Bausch Health Companies' stock. Their forecasts range from $17.00 to $55.00. On average, they anticipate Bausch Health Companies' share price to reach $34.80 in the next year. This suggests a possible upside of 18.7% from the stock's current price.
View analysts' price targets for Bausch Health Companies or view top-rated stocks among Wall Street analysts.

43 employees have rated Bausch Health Companies CEO Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among Bausch Health Companies' employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Bausch Health Companies include Alexion Pharmaceuticals (ALXN), Astellas Pharma (ALPMY), BeiGene (BGNE), Shiseido (SSDOY), Genmab A/S (GMAB), Royalty Pharma (RPRX), Genmab A/S (GNMSF), Takeda Pharmaceutical (TKPYY), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Horizon Therapeutics Public (HZNP), Alnylam Pharmaceuticals (ALNY), Catalent (CTLT), UCB (UCBJF), Viatris (VTRS) and Elanco Animal Health (ELAN).
View all of BHC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC).

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

Bausch Health Companies' stock is owned by many different institutional and retail investors. Top institutional investors include Glenview Capital Management LLC (4.36%), Morgan Stanley (1.97%), Laurion Capital Management LP (1.75%), Royal Bank of Canada (1.55%), Price T Rowe Associates Inc. MD (1.48%) and Fiera Capital Corp (0.96%). Company insiders that own Bausch Health Companies stock include Amy B Wechsler, Christina Ackermann, Eschenbach Andrew C Von, Holdings LP Valueact, John Paulson, Joseph C Papa, Mark C Mckenna, Sam Eldessouky, Schutter Richard U De and William D Humphries.
View institutional ownership trends for Bausch Health Companies.

BHC stock was sold by a variety of institutional investors in the last quarter, including Permian Investment Partners LP, Canyon Capital Advisors LLC, Renaissance Technologies LLC, Redwood Capital Management LLC, Glenview Capital Management LLC, BlackRock Inc., Lakewood Capital Management LP, and Price T Rowe Associates Inc. MD. Company insiders that have sold Bausch Health Companies company stock in the last year include Amy B Wechsler, Christina Ackermann, Sam Eldessouky, and William D Humphries.
View insider buying and selling activity for Bausch Health Companies or view top insider-selling stocks.

BHC stock was purchased by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Factorial Partners LLC, Thompson Siegel & Walmsley LLC, Voloridge Investment Management LLC, BNP Paribas Arbitrage SA, Royal Bank of Canada, Hillsdale Investment Management Inc., and Putnam Investments LLC. Company insiders that have bought Bausch Health Companies stock in the last two years include Christina Ackermann, Eschenbach Andrew C Von, Holdings LP Valueact, John Paulson, Joseph C Papa, Schutter Richard U De, and William D Humphries.
View insider buying and selling activity for Bausch Health Companies or or view top insider-buying stocks.

Shares of BHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BHC stock can currently be purchased for approximately $29.31.

Bausch Health Companies has a market capitalization of $10.50 billion and generates $8.03 billion in revenue each year. The company earns $-560,000,000.00 in net income (profit) each year or $3.99 on an earnings per share basis.

Bausch Health Companies employs 21,600 workers across the globe.

The official website for Bausch Health Companies is www.bauschhealth.com.

Bausch Health Companies is headquartered at 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8.

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company can be reached via phone at 514-744-6792 or via email at [email protected]